SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude rallies on fears that escalating Middle East conflict and attacks on tankers and energy infrastructure could disrupt oil supplies, with traders also citing tight inventories. The community is split between bulls expecting further gains and bears who see a crowded, speculation-driven war premium that could unwind if diplomacy advances or supply concerns ease.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Small caps are under pressure amid hotter inflation readings and concerns that interest rates may stay higher, with traders noting the Russell 2000s sensitivity to borrowing costs and its technical weakness. Some see oversold conditions and sector rotation as support for a rebound, while others expect further downside if key support fails.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a sharp selloff across AI infrastructure and neocloud stocks, fueled by worries about financing costs, debt, and whether AI buildout spending will earn adequate returns. Traders are split on whether the oversold rebound signals stabilization or is a bull trap, with some arguing Nebius is better positioned than more debt-heavy peers.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs new index rules have raised the possibility that Strategy could be removed from major benchmarks, fueling concerns about forced passive-fund selling and adding pressure amid Bitcoin volatility. Traders are split between expecting further downside and buying the dip, with dilution and the companys preferred-stock buyback strategy also drawing criticism; removal has not been confirmed.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStops reminder that its shareholder warrants are nearing expiration is driving attention, with traders focused on whether the shares can rise above the exercise price before the deadline. Bears expect the warrants to expire worthless, avoiding dilution, while bulls speculate that Ryan Cohen may take action to lift the stock or extend the deadline.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

CEO Angelos Stergious anniversary message about SELLASs next chapter with GPS and SLS009 has prompted speculation about an upcoming catalyst or buyout, though the post disclosed no clinical update. Traders remain focused on the blinded REGAL trials final-analysis trigger, debating whether the prolonged wait signals strong survival or simply leaves the outcome unknown; some view the post as reassurance, while others see it as routine anniversary remarks.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows is being linked to concerns about Trumps political standing ahead of the midterms and doubts about the companys business prospects, including Truth Social engagement. The discussion is overwhelmingly bearish, though some traders see a potential bounce or short squeeze.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

A sharp, volatile pullback has investors focused on whether CLS can hold support, with some traders buying the dip while others expect further declines. The selloff is being weighed against optimism about AI-infrastructure demand and an upcoming earnings report, though traders disagree on whether that optimism is already priced in.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

CIFRs convertible-note financing and resulting dilution concerns dominate discussion, compounded by a sharp selloff across AI and data-center peers. Traders criticize the companys financing and management while some remain bullish on its long-term AI infrastructure prospects and hope for a rebound.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs upcoming third-quarter earnings report is the main focus, with traders weighing expectations for another strong quarter against uncertainty around costs. Discussion also centers on NHTSAs review of the L87 V8 recall remedy after reports of post-repair engine failures, and whether the issue could add warranty or legal exposure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Discussion centers on VRAXs volatile, low-float swings and hopes for a short squeeze, with bullish chatter pointing to the Fosun deal, planned PAIS development, and limited shares while bears warn of pump-and-dump action, dilution, and weak follow-through; sentiment is sharply divided.

NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'

Equity

No plague case has been confirmed, and no government orders have been announced, but outbreak-linked stocks jumped anyway.

Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement PR...

Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds PR Newswire LONDON, July 10, 2026 LONDON, July 10, 2026...

Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds PR Newswire LONDON, July 9, 2026 LONDON, July 9, 2026 /PRNewswire/ -- Virax...

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers

Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million.
Forte Biosciences (NASDAQ:FBRX) stock roseread more...

These Companies Just Dropped Major Growth Catalysts

A wave of corporate announcements, from international distribution agreements and manufacturing leadership appointments to expanding government contracts and enterprise AI initiatives, several companies confirm strengthening revenue opportunities and long-term execution. $BLIS, $VRAX, $ENVX, $RKTO, $SPCX, $TDTH

Virax Biolabs Lands Strategic Southeast Asia Distribution Deal, Opening the Door to Commercial Revenue Across Six Countries

Virax Biolabs (NASDAQ:VRAX) has taken a meaningful step from product development toward commercial execution by signing an exclusive multi-country commercial supply agreement with Fosun Diagnostics, one of Asia's largest diagnostics organizations. While still an emerging biotechnology company, Virax is now positioned to begin generating near-term revenue from its commercially available ImmuneSelect research-use product line while continuing to develop its flagship ViraxImmune diagnostic platform.

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers

Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million.
Alnylam Pharmaceuticals (NASDAQ:ALNY) stockread more...

Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics

Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics PR Newswire LONDON, July 9, 2026 LONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the...

Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation

Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation PR Newswire LONDON, June 24, 2026 LONDON, June 24, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that...

Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The company was founded by James Foster and Cameron Shaw in 2013 and is headquartered in London, the United Kingdom.

Virax Biolabs Group Ltd - Ordinary Shares - Class A

Bullish Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$NVAX" data-symbol-id="NVAX" href="https://stocktwits.com/symbol/NVAX" target="_blank">NVAX</a> surged 20%, EBS gained 14%, ARCT rose 13% and MRNA climbed 7% amid the Russian plague scare.</li><li>The rally broadened to protective-equipment, antiviral and immune-profiling stocks, with LAKE gaining 15% and APT and NNVC each rising 13%.</li><li>Russian authorities called the regional situation stable, while the WHO assessed the public risk as low.</li></ul>A Russian lab worker’s unexplained death&nbsp;in a plague research institute sparked a rally across vaccine and biodefense stocks on Monday, with Novavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS) and Arcturus Therapeutics (ARCT) advancing as retail investors speculated about federal contracts and further gains.NVAX surged 20%,&nbsp;<a href="https://stocktwits.com/symbol/EBS">EBS</a> climbed 14%,&nbsp;<a href="https://stocktwits.com/symbol/ARCT">ARCT</a> gained 13% and&nbsp;<a href="https://stocktwits.com/symbol/MRNA">MRNA</a> rose 7%. Buying spread to protective-equipment suppliers, testing companies and antiviral developers as traders revived familiar outbreak bets.<img src="https://news.stocktwits-cdn.com/outbreak_rally_9d23a20745.png" alt="outbreak rally.png">The rally also extended to protective-equipment makers&nbsp;<a href="https://stocktwits.com/symbol/APT">Alpha Pro Tech (APT)</a>, which rose 13% on Monday, and&nbsp;<a href="https://stocktwits.com/symbol/LAKE">Lakeland Industries (LAKE)</a>, which gained 15%. Antiviral developer&nbsp;<a href="https://stocktwits.com/symbol/NNVC">NanoViricides (NNVC)</a> climbed 13%, immune-profiling company&nbsp;<a href="https://stocktwits.com/symbol/VRAX">Virax Biolabs (VRAX)</a> advanced 10%, and smallpox-drug maker&nbsp;<a href="https://stocktwits.com/symbol/SIGA">Siga Technologies (SIGA)</a> added 3%.&nbsp;Cancer-immunotherapy developer&nbsp;<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio (IBRX)</a>, which also featured in retail discussions about government demand, edged up 1%.&nbsp;&nbsp;<h2 class="st-heading-2">Trump’s Russia Offer Fuels Spending Hopes</h2>“We’ll help,” Trump said on Monday, calling the situation a “big problem for Russia,” Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/world/us/trump-says-us-will-help-russia-after-siberia-plague-institute-death-2026-10-05/">reported</a>. The remarks came after the death of Darya Shipilova, a 28-year-old lab technician at the Irkutsk Anti-Plague Research Institute in Siberia. She developed pneumonia of unknown origin, prompting quarantine measures and medical observation of people who had contact with her.Russia’s public health agency, Rospotrebnadzor, said samples contained no microorganisms associated with her professional duties and called the regional epidemiological situation stable.&nbsp;The WHO said that the risk to the general population appeared low based on available unofficial information. U.S. Secretary of State Marco Rubio also urged measured attention, calling the situation a “cause for focus,” according&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edition.cnn.com/2026/10/05/world/video/rubio-says-situation-in-russia-is-cause-for-focus-but-not-alarm">to</a> CNN.The uncertainty nevertheless gave traders a familiar catalyst: the prospect that heightened preparedness could lead to government purchases.<h2 class="st-heading-2">Vaccine Makers Ride Outbreak Bets</h2>Novavax, Moderna and Arcturus have commercial vaccines, but their products do not target plague. Novavax developed Nuvaxovid, a protein-based COVID-19 vaccine containing its Matrix-M adjuvant. Matrix-M enhances immune responses and can be incorporated into other vaccines, giving the company broader vaccine-development and licensing exposure.Moderna markets COVID-19 vaccines, including Spikevax, and the RSV vaccine mRESVIA. Its mRNA tech makes it a familiar name in emerging-pathogen trades.&nbsp;Meanwhile, Arcturus has the commercial COVID-19 vaccine Kostaive and is developing ARCT-2304, an experimental H5N1 pandemic-influenza vaccine. BARDA fully funds the candidate’s Phase 1 study.<h2 class="st-heading-2">Stockpile Suppliers And PPE Makers Rally</h2>Emergent has a direct connection to government purchasing through its medical-countermeasure portfolio. BioThrax and Cyfendus are anthrax vaccines, while ACAM2000 is a smallpox and mpox vaccine. Tembexa, another portfolio product, is a smallpox antiviral. Its $24 million BARDA contract modification for Cyfendus, announced last month, shows its procurement model.&nbsp;Siga supplies TPOXX, a smallpox antiviral, to the Strategic National Stockpile. Lakeland and Alpha Pro Tech provide protective equipment. Lakeland supplies protective clothing, while Alpha Pro Tech manufactures disposable garments, masks and face shields.&nbsp;<h2 class="st-heading-2">Antiviral And Immunotherapy Names Join Rally</h2>Virax Biolabs focuses on immune-response detection and T-cell profiling, including applications in post-acute infection syndromes such as Long COVID. NanoViricides is developing NV-387, an antiviral drug candidate. Because plague is bacterial, its rally reflects broader outbreak sentiment rather than an established plague-treatment opportunity.Meanwhile, ImmunityBio markets Anktiva, a cancer immunotherapy, and develops immune-cell platforms.<h2 class="st-heading-2">How Do Retail Traders Feel About Outbreak Bets?</h2>On Stocktwits, retail sentiment for NVAX and EBS was ‘extremely bullish’ amid ‘extremely high’ message volume. ARCT drew ‘bullish’ sentiment with ‘normal’ chatter, while MRNA sentiment remained ‘neutral’ despite ‘high’ message volume.&nbsp;One user on EBS&nbsp;<a href="https://stocktwits.com/KnuckleSandwich/message/665783238">said</a>: “Contract awards are in bound....good timing with the Russia plague news fueling the momentum!!” The user added: “See you at 15++.. Might even hit 20 by year-end!” Another user on NVAX&nbsp;<a href="https://stocktwits.com/TobySmith1366/message/665803930">sees</a> a return to “operation warp speed” and “throwing billions at NVAX.”One user on APT&nbsp;<a href="https://stocktwits.com/Paretoprincipal/message/665752847">drew parallels</a> with a previous outbreak trade: “Hantavirus took APT from $4.50 to $7.50 this May. The plague should take us even higher.” Another user on NNVC&nbsp;<a href="https://stocktwits.com/insanitywolftrading/message/665786543">noted</a> that “every time there is a pandemic fear this makes a massive run.”So far this year, NVAX has gained 87%, MRNA has surged 589% and ARCT has climbed 139%, while EBS remains down 41%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spcx-stock-musk-trillionaire-sequoia-maguire-investors-starting-to-understand-spacex/cZDsnwARBjv">SPCX Stock Makes Musk A Trillionaire Again: Sequoia's Maguire Says Investors Are Just 'Starting To Understand SpaceX'&nbsp;</a>

Alpha Pro Tech Ltd.

Arcturus Therapeutics Holdings Inc

Emergent Biosolutions Inc

ImmunityBio Inc

Lakeland Industries, Inc.

Moderna Inc

NanoViricides Inc

Novavax Inc

SIGA Technologies Inc

Virax Biolabs Group Ltd

SPDR S&P Biotech ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Stocktwits

SpaceX

Netflix Inc

Meta Platforms Inc

Which earnings release are you most looking forward to this week: 

Stocktwits Polls

$VRAX Wouldn't be surprised to see them announce another contract (even government) in near term.

Brian Thomson

$VRAX Cash + Current Assets = $7/share. Any kind of meaningful news here can send this to the moon. I'm in very heavy. Matter of patience on this as they are overdue on PAIS news.

$VRAX If Russia plague fears deepen things could get interesting here.  Trump to talk with Putin soon.

$VRAX quite possible with the position(s) by the current administration re: certain generalized aspects of the Virax platform...

$VRAX sold my 30k shares above 3. I know this stock is heavily shorted debating if I should buy back?

John Ciccarelli

Reclaim 2.40 and hold the retest / watch 2.63–2.65 then 2.90–3.01 / lose 2.26 and watch 2.14 then 2.02
$VRAX

Feed

News

Sentiment

Fundamentals

Info

VRAX Virax Biolabs Group Ltd

Fundamentals

Community Summary

Latest VRAX News